Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 4/20 | 1.00 |
| ▸ | GLRA2 | P23416 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PTAFR | P25105 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | GUSB | P08236 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ginkgolide A SCHEMBL13808829 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL14029426 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL29493161 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL340234 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL13702916 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL24818724 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkgolide A SCHEMBL340233 | 1.00 | GLRA1 (1.00) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| Ginkolide B SCHEMBL29384055 | 0.91 | PTAFR (0.83) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13702686 | 0.87 | GLRA1 (0.77) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13702895 | 0.87 | GLRA1 (0.77) | GLRA1GLRA2KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084755-B2 | Method for extracting and separating ginkgolides | CHENGDU BAIYU TECHNOLOGY PHARMACY CO., LTD. (CN) | 2015-07-21 | — | — | US | disclosed |
| US-9084755-B2 | Method for extracting and separating ginkgolides | CHENGDU BAIYU TECHNOLOGY PHARMACY CO., LTD. (CN) | 2015-07-21 | — | — | US | disclosed |
| US-20150044311-A1 | METHOD FOR EXTRACTING AND SEPARATING GINKGOLIDES | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2015-02-12 | — | — | US | disclosed |
| US-20150044311-A1 | METHOD FOR EXTRACTING AND SEPARATING GINKGOLIDES | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044311-A1 | METHOD FOR EXTRACTING AND SEPARATING GINKGOLIDES | COG8, CYP8B1, GTPBP10 | GLRA1 1288/4885GLRA2 1355/4885KMT2A 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.